Toth Financial Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.3K | Sell |
205
-5,900
| -97% | -$324K | ﹤0.01% | 475 |
|
|
2025
Q1 | $432K | Buy |
6,105
+5,900
| +2,878% | +$417K | 0.05% | 163 |
|
|
2024
Q4 | $13.5K | Hold |
205
| – | – | ﹤0.01% | 431 |
|
|
2024
Q3 | $14.4K | Hold |
205
| – | – | ﹤0.01% | 415 |
|
|
2024
Q2 | $16.9K | Hold |
205
| – | – | ﹤0.01% | 410 |
|
|
2024
Q1 | $17.9K | Hold |
205
| – | – | ﹤0.01% | 392 |
|
|
2023
Q4 | $19.8K | Hold |
205
| – | – | ﹤0.01% | 390 |
|
|
2023
Q3 | $18.1K | Hold |
205
| – | – | ﹤0.01% | 380 |
|
|
2023
Q2 | $17.8K | Hold |
205
| – | – | ﹤0.01% | 404 |
|
|
2023
Q1 | $19.9K | Hold |
205
| – | – | ﹤0.01% | 384 |
|
|
2022
Q4 | $21.2K | Hold |
205
| – | – | ﹤0.01% | 373 |
|
|
2022
Q3 | $17K | Sell |
205
-95
| -32% | -$7.88K | ﹤0.01% | 389 |
|
|
2022
Q2 | $25K | Sell |
300
-20
| -6% | -$1.67K | ﹤0.01% | 342 |
|
|
2022
Q1 | $25K | Hold |
320
| – | – | ﹤0.01% | 358 |
|
|
2021
Q4 | $28K | Hold |
320
| – | – | ﹤0.01% | 350 |
|
|
2021
Q3 | $25K | Hold |
320
| – | – | ﹤0.01% | 366 |
|
|
2021
Q2 | $27K | Hold |
320
| – | – | ﹤0.01% | 336 |
|
|
2021
Q1 | $24K | Hold |
320
| – | – | ﹤0.01% | 355 |
|
|
2020
Q4 | $28K | Hold |
320
| – | – | ﹤0.01% | 298 |
|
|
2020
Q3 | $24K | Hold |
320
| – | – | ﹤0.01% | 288 |
|
|
2020
Q2 | $39K | Hold |
320
| – | – | 0.01% | 238 |
|
|
2020
Q1 | $27K | Buy |
320
+20
| +7% | +$1.69K | 0.01% | 213 |
|
|
2019
Q4 | $25K | Hold |
300
| – | – | 0.01% | 243 |
|
|
2019
Q3 | $20K | Hold |
300
| – | – | ﹤0.01% | 275 |
|
|
2019
Q2 | $26K | Hold |
300
| – | – | 0.01% | 254 |
|
|
2019
Q1 | $27K | Sell |
300
-100
| -25% | -$9K | 0.01% | 240 |
|
|
2018
Q4 | $34K | Hold |
400
| – | – | 0.01% | 207 |
|
|
2018
Q3 | $39K | Hold |
400
| – | – | 0.01% | 216 |
|
|
2018
Q2 | $38K | Hold |
400
| – | – | 0.01% | 221 |
|
|
2018
Q1 | $32K | Hold |
400
| – | – | 0.01% | 230 |
|
|
2017
Q4 | $36K | Buy |
+400
| New | +$36K | 0.01% | 229 |
|